9Suppliers
1Customers
2Debt Items
20Related Chains

Tango Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
ERASCA ERASCA 90% Erasca is supplying ERAS-0015 at no cost.
CLINICAL-SUPPLY-MANUFACTURING-VENDORS CLINICAL-SUPPLY-MANUFACTURING-VENDORS 80% The Company enters into contracts in the normal course of business with other vendors for clinical supply manufacturing or other preclinical and clinical services.
CONTRACT-RESEARCH-ORGANIZATIONS CONTRACT-RESEARCH-ORGANIZATIONS 80% The Company enters into certain agreements with contract research organizations in the ordinary course of business that contain indemnification provisions.
PROFESSIONAL-CONSULTANTS PROFESSIONAL-CONSULTANTS 80% The Company enters into contracts in the normal course of business with professional consultants for expert advice.
BUSINESS-PARTNERS BUSINESS-PARTNERS 70% The Company enters into certain agreements with business partners in the ordinary course of business that contain indemnification provisions.
CLINICAL-TRIAL-SITES CLINICAL-TRIAL-SITES 70% The Company enters into certain agreements with clinical trial sites in the ordinary course of business that contain indemnification provisions.
CONSTRUCTION-COMPANIES CONSTRUCTION-COMPANIES 70% The Company enters into certain agreements with construction companies in the ordinary course of business that contain indemnification provisions.
DIRECTORS-AND-OFFICERS DIRECTORS-AND-OFFICERS 70% The Company enters into certain agreements with directors and officers in the ordinary course of business that contain indemnification provisions.
LANDLORDS LANDLORDS 70% The Company enters into certain agreements with landlords in the ordinary course of business that contain indemnification provisions.

Tango Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
GILEAD GILEAD 90% The Company identified a single combined performance obligation under the Gilead Agreement consisting of the research services and continued participation on the joint steering committee during the r…

Tango Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
TNGX-DEBT Debt stack $32.8M 90% Market cache reports total debt of $32.8M.
TNGX-DEBT-13038 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-06-30.

Tango Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Tango Therapeutics, Inc..

Tango Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
TNGX-OWNER-WOODLINE-PARTNERS-LP Woodline Partners LP 90% 13F overlay lists Woodline Partners LP as top holder; 196 tracked holders.

Tango Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
RCUS Arcus Biosciences, Inc. 100.00 2
KYTX Kyverna Therapeutics, Inc. 100.00 2
RPRX Royalty Pharma plc 100.00 2
PYXS Pyxis Oncology, Inc. 100.00 2
SNYNF Sanofi 100.00 2
KYMR Kymera Therapeutics, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
ASMB Assembly Biosciences, Inc. 100.00 2
NRIX Nurix Therapeutics, Inc. 100.00 2
CRIS Curis, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
MGNX MacroGenics, Inc. 100.00 2
GLMD Galmed Pharmaceuticals Ltd. 100.00 2
GDTC CytoMed Therapeutics Limited 100.00 2
CABA Cabaletta Bio, Inc. 100.00 2
CAH Cardinal Health, Inc. 100.00 2
IBIO iBio, Inc. 100.00 2
AVIR Atea Pharmaceuticals, Inc. 100.00 2
MCK McKesson Corporation 100.00 2